Iovance Biotherapeutics Inc. | Shareholder Proxy Access at Iovance Therapeutics Inc.

Resolution details
Company ticker
IOVA
Resolution ask
Adopt or amend a policy
ESG theme
  • Governance
ESG sub-theme
  • Shareholder rights
Company HQ country
United States
Whereas clause
Shareholders request our Board of directors take the steps necessary to enable shareholders, without limits on group size, to aggregate their shares to equal 3% of our stock owned continuously for 3 years to enable shareholder proxy access with the following essential provision: • Nominating shareholders and unlimited groups of shareholders must have owned at least 3% of the Company’s outstanding shares of common stock continuously for a period of at least 3 years. • The essential feature requested may allow employee owners to combine with institutional investors to nominate candidates.